<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02472535</url>
  </required_header>
  <id_info>
    <org_study_id>CB8025-21427</org_study_id>
    <nct_id>NCT02472535</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of MBX-8025 in Patients With HoFH</brief_title>
  <official_title>A 12-week, Open-label, Dose-escalating, Phase 2 Study to Evaluate the Effects of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in
      patients with Homozygous Familial Hypercholesterolemia (HoFH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, single arm, non-controlled, dose ascending (50 mg/day, 100 mg/day and 200 mg/day)
      with three consecutive dose escalation periods.

      After signing an informed consent subject will enter a screening period and a run-in
      stabilization period. At the end of run-in period patients will enter treatment phase.
      MBX-8025 in ascending doses (50 mg, 100 mg, and 200 mg) will be given within three
      consecutive 4 weeks periods, for a total of 12 weeks. At the end of treatment, subjects will
      enter a follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Absolute and percentage (%) reduction in serum LDL-C at any point from baseline through Week 16.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol (TC)</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Absolute and percentage change at any point from baseline through Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density lipoprotein (HDL) cholesterol [HDL-C]</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Absolute and percentage change at any point from baseline through Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very Low-Density Lipoprotein (VLDL)</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Absolute and percentage change at any point from baseline through Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non HDL-C</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Absolute and percentage change at any point from baseline through Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remnant-like Particle (RLP-C)</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Absolute and percentage change at any point from baseline through Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B (Apo B)</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Absolute and percentage change at any point from baseline through Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein A-I (Apo A-I)</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Absolute and percentage change at any point from baseline through Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipoprotein</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Absolute and percentage change at any point from baseline through Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Triglyceride (TG)</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Absolute and percentage change at any point from baseline through Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein C-III (Apo CIII)</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Absolute and percentage change at any point from baseline through Week 16</description>
  </secondary_outcome>
  <other_outcome>
    <measure>C reactive protein hs-(CRP)</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Absolute and percentage change at any point from baseline through Week 16</description>
  </other_outcome>
  <other_outcome>
    <measure>MBX-8025 Plasma Concentration Levels</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Blood samples for the plasma concentration determination of MBX-8025 and its metabolites (M1, M2 and M3) collected pre-dose at the following visits: 4, 5, 6, 7, 8 and 9.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Measures: Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Complete characterization of Adverse Events (AE), Biochemistry and Hematology</description>
  </other_outcome>
  <other_outcome>
    <measure>Proprotein convertase subtilisin/kexin type 9 (PCSK-9)</measure>
    <time_frame>12-Weeks</time_frame>
    <description>Absolute and percentage change at any point from baseline through Week 16 for the following: Proprotein convertase subtilisin/kexin type 9 (PCSK-9)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>placebo, MBX-8025 50 mg, 100 mg or 200 mg capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Run-In Period: Placebo</intervention_name>
    <description>2 capsules, once a day for two weeks</description>
    <arm_group_label>placebo, MBX-8025 50 mg, 100 mg or 200 mg capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025 50 mg (Dose Escalation Period 1)</intervention_name>
    <description>1 capsule once a day for 4 weeks
(MBX-8025 50 mg capsule)</description>
    <arm_group_label>placebo, MBX-8025 50 mg, 100 mg or 200 mg capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)</intervention_name>
    <description>1 capsule once a day for 4 weeks
(MBX-8025 50 mg or 100 mg capsule)</description>
    <arm_group_label>placebo, MBX-8025 50 mg, 100 mg or 200 mg capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)</intervention_name>
    <description>1 or 2 capsules once a day for 4 weeks
(MBX-8025 50 mg, 100 mg or two (2) 100 mg capsules)</description>
    <arm_group_label>placebo, MBX-8025 50 mg, 100 mg or 200 mg capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must have given written informed consent (signed and dated) and any authorizations
             required by local law and be able to comply with all study requirements.

          2. Male or female with HoFH confirmed by genotype (two mutant alleles at the LDL-Receptor
             (LDL-R) gene locus or double heterozygotes LDL-R/Apo-B).

          3. 18 years of age or older.

          4. Existing lipid lowering therapies (statins, cholesterol absorption inhibitors, bile
             acid sequestrants, nicotinic acid and their combinations, low-density lipoprotein
             (LDL) LDL-C apheresis) on a stable regimen for at least four weeks before screening
             visit.

          5. Stable lipid lowering diet compatible with a Step I diet of the American Heart
             Association (AHA).

          6. Fasting LDL-C ≥ 4.8 mmol/L (≥ 185.6 mg/dL) during screening.

          7. For females or males of reproductive potential, use of at least one barrier
             contraceptive and a second effective birth control method during the study and for at
             least two weeks after the last dose.

        Exclusion Criteria:

          1. Treatment with lomitapide or mipomersen within two months of screening.

          2. Heart Failure (HF) with New York Heart Association (NYHA) class III and class IV or a
             Left ventricular ejection fraction (LVEF) of less than 30%.

          3. Uncontrolled cardiac arrhythmia during the past three months of screening.

          4. Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary
             artery bypass graft or stroke during the past three months of screening.

          5. Planned cardiac surgery, or planned revascularization, in the next four months.

          6. Uncontrolled hypertension.

          7. Aspartate transaminase (AST) or Alanine transaminase (ALT) ≥ 3 times the Upper Limit
             of Normal (ULN).

          8. Unexplained creatine kinase (CK) ≥ 5 times the upper limit of normal (ULN).

          9. For females, pregnancy or breast-feeding.

         10. Any other condition(s) that would compromise the safety of the patient or compromise
             the quality of the clinical study as judged by the Investigator and/or Medical
             Monitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pol F Boudes, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>CymaBay Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ecogene-21</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinologie metabolisme et prevention cardiovasulaire, Institut E3M et IHU cardiometabolique (ICAN), Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75 013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radbound UMC</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipidklinikken, Oslo Universitetssykehus</name>
      <address>
        <city>Oslo</city>
        <zip>N-0373</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2015</study_first_submitted>
  <study_first_submitted_qc>June 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2015</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HoFH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

